Working… Menu

Evaluation of Efficacy and Safety of Ialuset Cream and Gauze in Second-degree Burns on Child

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04124133
Recruitment Status : Completed
First Posted : October 11, 2019
Last Update Posted : October 11, 2019
Information provided by (Responsible Party):
Laboratoires Genévrier

Brief Summary:

Observational retrospective monocentric study occured in the univeristy hospital center of Bensançon the department of pediatric surgery.

Data of patients treated in the hospital between January 2016 and January 2019 have been collected.

Condition or disease Intervention/treatment
Second-degree Burn of Children Device: dressing with hyaluronic acid

Detailed Description:

Coordinator investigator have put in place a protocol care for children with second degree burns since 2016.

It consists in detersion and cleaning of wound, application of ialuset cream and gauzepad (hyaluronic acid) during 21 days. After 21 days if patients are not healed, physician consider to perform grafting

Layout table for study information
Study Type : Observational
Actual Enrollment : 92 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Observational Retrospective Study Evaluating Efficacy and Safety of Ialuset Cream or Gauzepad in Second Degree Burns Use for Children
Actual Study Start Date : December 10, 2018
Actual Primary Completion Date : April 18, 2019
Actual Study Completion Date : April 18, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Intervention Details:
  • Device: dressing with hyaluronic acid
    Application of ialuset cream or gauzepad (hyaluronic acid)

Primary Outcome Measures :
  1. Patient rate with complete healing [ Time Frame: 21 days ]
    pourcentage of patient with 100% of reepithelilisation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 15 Years   (Child)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Children from 1month to 15 years with a second degree burn

Inclusion Criteria:

  • second-degree burns
  • less than 20% of the body surface
  • less than 15 years old
  • treated within 24 hours
  • 1st line of treatment with ialuset
  • treated at the center between 2016 and 2019

Exclusion Criteria:

  • patient who refused data collection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04124133

Layout table for location information
CHU Besançon
Besançon, France
Sponsors and Collaborators
Laboratoires Genévrier
Layout table for investigator information
Principal Investigator: Arnaud Fotso Kamdem CHU Besançon

Layout table for additonal information
Responsible Party: Laboratoires Genévrier Identifier: NCT04124133     History of Changes
Other Study ID Numbers: CHILD study
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents